Cefiderocol: A new cephalosporin stratagem against multidrug resistant gram-negative bacteria.
Sharon Ong'utiMary CzechElizabeth RobilottiMarisa K HolubarPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
Cefiderocol is a novel injectable siderophore cephalosporin which hijacks the bacterial iron transport machinery to facilitate cell entry and achieve high periplasmic concentrations. It has broad in vitro activity against gram-negative bacteria, including multidrug resistant (MDR) organisms like carbapenem resistant Enterobacterales (CRE), carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii. It was approved by the Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections and nosocomial pneumonia based on clinical trials demonstrating noninferiority to comparators. In this review, we summarize the available in vitro and clinical data, including recent evidence from 2 phase III clinical trials (APEKS-NP and CREDIBLE-CR), and discuss the place of cefiderocol in the clinician's armamentarium against MDR gram-negative infections.
Keyphrases
- gram negative
- multidrug resistant
- acinetobacter baumannii
- clinical trial
- phase iii
- drug administration
- drug resistant
- urinary tract infection
- open label
- phase ii
- klebsiella pneumoniae
- pseudomonas aeruginosa
- double blind
- single cell
- electronic health record
- study protocol
- randomized controlled trial
- placebo controlled
- escherichia coli
- machine learning
- stem cells
- smoking cessation
- data analysis
- iron deficiency
- staphylococcus aureus
- replacement therapy